255 related articles for article (PubMed ID: 27508193)
1. Early α-fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib.
Lee S; Kim BK; Kim SU; Park JY; Kim do Y; Ahn SH; Han KH
J Hepatocell Carcinoma; 2015; 2():39-47. PubMed ID: 27508193
[TBL] [Abstract][Full Text] [Related]
2. Early α-fetoprotein response as a predictor for clinical outcome after localized concurrent chemoradiotherapy for advanced hepatocellular carcinoma.
Kim BK; Ahn SH; Seong JS; Park JY; Kim DY; Kim JK; Lee DY; Lee KH; Han KH
Liver Int; 2011 Mar; 31(3):369-76. PubMed ID: 21083802
[TBL] [Abstract][Full Text] [Related]
3. Value of α-fetoprotein as an early biomarker for treatment response to sorafenib therapy in advanced hepatocellular carcinoma.
Sánchez AIP; Roces LV; García IZ; López EL; Hernandez MAC; Parejo MIB; Peña-Díaz J
Oncol Lett; 2018 Jun; 15(6):8863-8870. PubMed ID: 29805623
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib.
Kawaoka T; Aikata H; Murakami E; Nakahara T; Naeshiro N; Tanaka M; Honda Y; Miyaki D; Nagaoki Y; Takaki S; Hiramatsu A; Waki K; Takahashi S; Chayama K
Oncology; 2012; 83(4):192-200. PubMed ID: 22890083
[TBL] [Abstract][Full Text] [Related]
5. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma.
Shao YY; Lin ZZ; Hsu C; Shen YC; Hsu CH; Cheng AL
Cancer; 2010 Oct; 116(19):4590-6. PubMed ID: 20572033
[TBL] [Abstract][Full Text] [Related]
6. Propensity Score Matching Analysis of Changes in Alpha-Fetoprotein Levels after Combined Radiotherapy and Transarterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.
Jeong Y; Yoon SM; Han S; Shim JH; Kim KM; Lim YS; Lee HC; Kim SY; Park JH; Lee SW; Ahn SD; Choi EK; Kim JH
PLoS One; 2015; 10(8):e0135298. PubMed ID: 26252472
[TBL] [Abstract][Full Text] [Related]
7. Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib.
Nakazawa T; Hidaka H; Takada J; Okuwaki Y; Tanaka Y; Watanabe M; Shibuya A; Minamino T; Kokubu S; Koizumi W
Eur J Gastroenterol Hepatol; 2013 Jun; 25(6):683-9. PubMed ID: 23395995
[TBL] [Abstract][Full Text] [Related]
8. Changes in serum α-fetoprotein level predicts treatment response and survival in hepatocellular carcinoma patients and literature review.
Chou WC; Lee CL; Yang TS; Huang CY; Teng W; Tseng YT; Chen JS; Lin YC; Hou MM; Chang HH; Chia-Hsun Hsieh J
J Formos Med Assoc; 2018 Feb; 117(2):153-163. PubMed ID: 28392193
[TBL] [Abstract][Full Text] [Related]
9. Transarterial chemoembolization with/without cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma.
Wang C; Lu Y; Wang H; Gao X; Bai W; Qu J; Xu G; Zhang Z; Zeng Z; Zhou L; An L; Lv J; Yang Y
Exp Ther Med; 2012 Aug; 4(2):188-196. PubMed ID: 23139708
[TBL] [Abstract][Full Text] [Related]
10. Early Clinical Response after 2 Weeks of Sorafenib Therapy Predicts Outcomes and Anti-Tumor Response in Patients with Advanced Hepatocellular Carcinoma.
Kuzuya T; Ishigami M; Ishizu Y; Honda T; Hayashi K; Katano Y; Hirooka Y; Ishikawa T; Nakano I; Goto H
PLoS One; 2015; 10(9):e0138776. PubMed ID: 26421430
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma.
Personeni N; Bozzarelli S; Pressiani T; Rimassa L; Tronconi MC; Sclafani F; Carnaghi C; Pedicini V; Giordano L; Santoro A
J Hepatol; 2012 Jul; 57(1):101-7. PubMed ID: 22414760
[TBL] [Abstract][Full Text] [Related]
12. Prognostic role of serial alpha-fetoprotein levels in hepatocellular carcinoma treated with locoregional therapy.
Paul SB; Sahu P; Sreenivas V; Nadda N; Gamanagatti SR; Nayak B; Shalimar S; Acharya SK
Scand J Gastroenterol; 2019 Sep; 54(9):1132-1137. PubMed ID: 31483691
[No Abstract] [Full Text] [Related]
13. The outcome of sorafenib monotherapy on hepatocellular carcinoma with portal vein tumor thrombosis.
Kuo YH; Wu IP; Wang JH; Hung CH; Rau KM; Chen CH; Kee KM; Hu TH; Lu SN
Invest New Drugs; 2018 Apr; 36(2):307-314. PubMed ID: 28466374
[TBL] [Abstract][Full Text] [Related]
14. Liver stiffness in magnetic resonance elastography is prognostic for sorafenib-treated advanced hepatocellular carcinoma.
Kim B; Kim SS; Cho SW; Cheong JY; Huh J; Kim JK; Lee JH; Ahn HR; Cho HJ
Eur Radiol; 2021 Apr; 31(4):2507-2517. PubMed ID: 33033862
[TBL] [Abstract][Full Text] [Related]
15. Comparison of α-Fetoprotein Criteria and Modified Response Evaluation Criteria in Solid Tumors for the Prediction of Overall Survival of Patients with Hepatocellular Carcinoma after Transarterial Chemoembolization.
Zhang YQ; Jiang LJ; Wen J; Liu DM; Huang GH; Wang Y; Fan WZ; Li JP
J Vasc Interv Radiol; 2018 Dec; 29(12):1654-1661. PubMed ID: 30396842
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: a Korean multicenter study.
Lee S; Kim BK; Kim SU; Park SY; Kim JK; Lee HW; Park JY; Kim DY; Ahn SH; Tak WY; Kweon YO; Lee JI; Lee KS; Kim HJ; Han KH
J Gastroenterol Hepatol; 2014; 29(7):1463-9. PubMed ID: 25273508
[TBL] [Abstract][Full Text] [Related]
17. Early decrease in α-fetoprotein, but not des-γ-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma.
Kuzuya T; Asahina Y; Tsuchiya K; Tanaka K; Suzuki Y; Hoshioka T; Tamaki S; Kato T; Yasui Y; Hosokawa T; Ueda K; Nakanishi H; Itakura J; Takahashi Y; Kurosaki M; Izumi N
Oncology; 2011; 81(3-4):251-8. PubMed ID: 22116493
[TBL] [Abstract][Full Text] [Related]
18. Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma.
Faivre S; Santoro A; Kelley RK; Gane E; Costentin CE; Gueorguieva I; Smith C; Cleverly A; Lahn MM; Raymond E; Benhadji KA; Giannelli G
Liver Int; 2019 Aug; 39(8):1468-1477. PubMed ID: 30963691
[TBL] [Abstract][Full Text] [Related]
19. [Comparison of therapeutics effects of transcatheter arterial chemoembolization combined with iodine-125 seed implantation and sorafenib for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis].
Luo J; Zheng JP; Shao GL; Wen S; Guo LW; Zeng H; Zhang L; Qian CY; Hao WY
Zhonghua Gan Zang Bing Za Zhi; 2018 Apr; 26(4):298-304. PubMed ID: 29996343
[No Abstract] [Full Text] [Related]
20. Treating Advanced Hepatocellular Carcinoma with Sorafenib: A 10-Year Single Center Experience.
Presa Ramos J; Tavares S; Barreira A; Pimenta JL; Carvalho S; Carrola P; Pinho I
GE Port J Gastroenterol; 2023 Jun; 30(3):213-220. PubMed ID: 37387721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
